logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research

The 7th Congress of Patients’ Organisations, organised by the POP, analyses the application of the new European Regulation on Clinical Trials.

Farmaindustria’s director general, Juan Yermo, stresses that this regulation is more demanding in terms of procedure and deadlines, and that this requires centres with sufficient resources and infrastructure to prevent researchers from wasting time on administrative activities.

farmaindustria.es

 

Juan Antonio Da Silva, president of the Spanish Cystic Fibrosis Federation (FEFQ); Juan Estévez, head of the Clinical Trials Area of the Department of Medicines for Human Use of the Spanish Agency for Medicines and Health Products (Aemps); Mencía de Lemus, member of the Committee for Advanced Therapies of the European Medicines Agency (EMA), and Juan Yermo, director general of Farmaindustria.

 

31 January 2023 marked the start of the implementation of the new European Clinical Trials Regulation, which harmonises the submission, assessment and monitoring processes for clinical trials in the region, with the aim of speeding them up and, consequently, getting new, effective and safe medicines to the people who need them sooner.

This milestone opens up a range of opportunities for all those involved in the development of biomedical research and especially for patients, for whom clinical trials are a source of hope when a treatment to cure or palliate their disease is not yet available. “We are facing a real opportunity to support clinical trials in order to turn the European Union (EU) into a hub for clinical research, to promote the development of quality, safe and effective medicines and to better integrate this research into the European health system,” said the director general of Farmaindustria, Juan Yermo, on Thursday at the 7th Congress of Patients’ Organisations, which is being held these days in Madrid and organised by the Platform of Patients’ Organisations (POP).

However, he continued, “this regulation is more demanding in terms of procedure and deadlines, and this requires hospitals to have highly qualified teams trained in the entire clinical research process, as well as being equipped with the necessary resources and infrastructure to prevent researchers from having to waste time on administrative activities”.

Spain was the first EU country to adopt the new European regulation, with Royal Decree 1090/2015, which has had a direct impact in terms of gaining an advantage over other Member States. This has meant that 58% of the clinical trials launched last year in Spain (almost twice as many as 20 years ago) now correspond to the early stages of research, phases I and II, which means that patients can access promising therapies even earlier.

Likewise, clinical trials in the paediatric population have been increasing since 2016 to exceed 160 in 2022, according to data from the Spanish Clinical Trials Register (REEC). The same is happening with research in rare diseases. A total of 924 clinical trials were approved in 2022, of which approximately 25% focus on rare diseases.

Spain has consolidated its leadership in clinical trials in recent years and can confidently face new challenges, such as the implementation of this new European Clinical Trials Regulation. “Trials not only offer new hope for patients, but also have very positive economic consequences for healthcare systems,” stressed Yermo. They attract funding from the sponsoring pharmaceutical companies to the participating centres, “as well as savings for the NHS”. In addition, they add reputation, experience and knowledge to the healthcare professionals who carry them out, placing them at the scientific forefront, which they can apply in their healthcare work.

Patients involved throughout the clinical trial process

In addition to these benefits, there is the challenge of involving the patient in the entire clinical trial process. “The steps that have been taken so far are of great value, but we must not stop, because we have great challenges ahead, such as encouraging the inclusion in trials of more diverse population groups, training and information for patients in biomedical research, as well as explaining to society the value of sharing and reusing data, with ethical and legal guarantees, to make research more efficient. Patients must also be involved in the design of informed consent forms, which are complex, lengthy and not always easy to understand,” Yermo said.

To address these issues, he pointed out the need to promote networked clinical research, as well as decentralisation initiatives, “on which we are already working with the Aemps”, and digitisation.

Finally, Yermo pointed out that this regulation is part of a larger strategy, which includes other important measures such as the development of the European Health Data Space or the revision of pharmaceutical legislation. Currently, only 22% of new treatments originate in Europe, while 47% come from the United States. This loss of European competitiveness compared to other markets that have shown greater growth has a direct implication for citizens, as “they are exposed to less access to new medicines or the possibility of participating in innovative clinical trials”, he explained. “Let us not miss the opportunity to continue to make Spain a benchmark country in clinical trials. And to do research with patients and not just for patients, which is how we have been working for years in the pharmaceutical industry”.

The director general of Farmaindustria shared a discussion with Juan Estévez, head of the Clinical Trials Area of the Department of Medicines for Human Use of the Spanish Agency for Medicines and Health Products (Aemps); Mencía de Lemus, member of the Committee for Advanced Therapies of the European Medicines Agency (EMA), and Juan Antonio Da Silva, president of the Spanish Federation of Cystic Fibrosis (FEFQ).

Related entries

13 May, 2025

Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years


Leer más
12 May, 2025

Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.


Leer más
8 May, 2025

Spain, a European success story in clinical trials of new drugs


Leer más

Recent Posts

  • Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years
  • Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.
  • Spain, a European success story in clinical trials of new drugs
  • Joint position on the draft Medicines and Medical Devices Law
  • The global pharmaceutical industry had 12,700 drugs in development by 2024

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

MADRID DELEGATION

+34 674 575 115
28010 Madrid

Links of interest

  • Legal warning
  • Privacy policy
  • Cookies policy
  • Contact

© 2025 Distefar del Sur SL. All rights reserved. agencianodo.com

  • No translations available for this page
  • Contact
  • Private Zone
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.